8-K Announcements
6Material company update
Feb 13, 2026·SEC
Material company update
Jan 12, 2026·SEC
Material company update
Nov 13, 2025·SEC
Orchestra BioMed Holdings, Inc.(OBIO)Earnings, Financials & Key Ratios
OBIO•NASDAQ
$4.11
$232M mkt cap·Price updated May 6, 2026
AboutOrchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.Show more
- Revenue$33M+1169.2%
- EBITDA-$52M+19.0%
- Net Income-$53M+13.2%
- EPS (Diluted)-1.11+33.1%
- Gross Margin99.43%+7.8%
- EBITDA Margin-154.73%+93.6%
- Operating Margin-154.73%+93.7%
- Net Margin-158.16%+93.2%
- ROE-122.4%-1.3%
- ROIC-162.6%-11.9%
- Debt/Equity0.03-93.7%
OBIO Key Insights
Orchestra BioMed Holdings, Inc. (OBIO) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong 5Y sales CAGR of 42.5%
✗Weaknesses
- ✗Negative free cash flow
- ✗Shares diluted 100.0% in last year
- ✗Expensive at 2946.2x book value
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
OBIO Price & Volume
Orchestra BioMed Holdings, Inc. (OBIO) stock price & volume — 10-year historical chart
Loading chart...
OBIO Growth Metrics
Orchestra BioMed Holdings, Inc. (OBIO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years42.48%
3 Years111.62%
TTM1169.22%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM13.22%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM33.13%
Return on Capital
10 Years-92.59%
5 Years-95.31%
3 Years-72.95%
Last Year-65.54%
OBIO Recent Earnings
Orchestra BioMed Holdings, Inc. (OBIO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 6/12 qtrs (55%)
Q2 2026Latest
Mar 12, 2026EPS
$0.26
Est $0.38
+168.4%
Revenue
$31M
Est $931,000
+3220.8%
Q4 2025
Nov 10, 2025EPS
$0.40
Est $0.38
-5.3%
Revenue
$861,000
Est $741,400
+16.1%
Q3 2025
Aug 12, 2025EPS
$0.50
Est $0.51
+2.0%
Revenue
$836,000
Est $778,833
+7.3%
Q2 2025
Apr 2, 2025EPS
$0.43
Est $0.43
+0.0%
Revenue
$253,000
Est $522,330
-51.6%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 12, 2026 | $0.26vs $0.38+168.4% | $31Mvs $931,000+3220.8% |
| Q4 2025 | Nov 10, 2025 | $0.40vs $0.38-5.3% | $861,000vs $741,400+16.1% |
| Q3 2025 | Aug 12, 2025 | $0.50vs $0.51+2.0% | $836,000vs $778,833+7.3% |
| Q2 2025 | Apr 2, 2025 | $0.43vs $0.43+0.0% | $253,000vs $522,330-51.6% |
Based on last 12 quarters of dataView full earnings history →
OBIO Peer Comparison
Orchestra BioMed Holdings, Inc. (OBIO) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NVCR | 1.88B | 16.50 | -13.52 | 8.28% | -25.66% | -50.82% | 0.85 | |
 XTNT | 80.8M | 0.58 | -4.81 | 28.44% | 1.32% | 3.77% | 0.82 | |
 BSX | 83.23B | 56.00 | 28.87 | 19.87% | 14.4% | 12.4% | 0.51 | |
 MDT | 99.48B | 77.60 | 21.50 | 3.62% | 13% | 9.45% | 0.59 | |
 ABT | 149.97B | 86.25 | 11.29 | 4.59% | 31.88% | 27.26% | 0.32 | |
 SYK | 111.96B | 292.33 | 34.80 | 11.16% | 12.92% | 15.04% | 0.66 | |
 EW | 47.97B | 83.20 | 45.46 | 11.55% | 17.64% | 10.35% | 0.07 | |
 LIVN | 3.62B | 66.26 | -14.89 | 10.74% | 7.47% | 9.13% | 0.39 |
Compare OBIO vs Peers
Orchestra BioMed Holdings, Inc. (OBIO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
OBIO Income Statement
Orchestra BioMed Holdings, Inc. (OBIO) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|
| Sales/Revenue | 5.7M | -782K | 3.53M | 2.76M | 2.64M | 33.48M |
| Revenue Growth % | - | -113.71% | 551.79% | -21.88% | -4.42% | 1169.22% |
| Cost of Goods Sold | 145K | 199K | 322K | 186K | 204K | 190K |
| COGS % of Revenue | 2.54% | -25.45% | 9.11% | 6.74% | 7.73% | 0.57% |
| Gross Profit | 5.56M▲ 0% | -981K▼ 117.7% | 3.21M▲ 427.3% | 2.57M▼ 19.8% | 2.43M▼ 5.4% | 33.29M▲ 1267.8% |
| Gross Margin % | 97.46% | 125.45% | 90.89% | 93.26% | 92.27% | 99.43% |
| Gross Profit Growth % | - | -117.65% | 427.32% | -19.84% | -5.44% | 1267.79% |
| Operating Expenses | 24.31M | 20.82M | 35.87M | 54.08M | 66.73M | 85.1M |
| OpEx % of Revenue | 426.27% | -2662.15% | 1015.23% | 1959.42% | 2529.76% | 254.16% |
| Selling, General & Admin | 10.83M | 7.93M | 13.92M | 20.26M | 23.93M | 26.91M |
| SG&A % of Revenue | 189.95% | -1013.81% | 394.08% | 733.99% | 907.16% | 80.38% |
| Research & Development | 13.48M | 12.89M | 21.95M | 33.82M | 42.8M | 58.19M |
| R&D % of Revenue | 236.31% | -1648.34% | 621.14% | 1225.43% | 1622.59% | 173.78% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -18.75M▲ 0% | -21.8M▼ 16.2% | -32.66M▼ 49.8% | -51.51M▼ 57.7% | -64.3M▼ 24.8% | -51.81M▲ 19.4% |
| Operating Margin % | -328.81% | 2787.6% | -924.34% | -1866.16% | -2437.49% | -154.73% |
| Operating Income Growth % | - | -16.25% | -49.81% | -57.72% | -24.84% | 19.43% |
| EBITDA | -18.61M | -21.62M | -32.44M | -51.22M | -63.99M | -51.81M |
| EBITDA Margin % | -326.41% | 2764.45% | -918.06% | -1855.76% | -2425.82% | -154.73% |
| EBITDA Growth % | - | -16.13% | -50.04% | -57.91% | -24.94% | 19.04% |
| D&A (Non-Cash Add-back) | 137K | 181K | 222K | 287K | 308K | 0 |
| EBIT | -18.75M | -21.8M | -32.66M | -51.51M | -64.3M | 0 |
| Net Interest Income | 331K | -927K | 50K | 3.85M | 3.36M | 0 |
| Interest Income | 331K | 0 | 50K | 3.85M | 3.36M | 0 |
| Interest Expense | 0 | 927K | 0 | 0 | 0 | -1.15M |
| Other Income/Expense | -2.6M | -1.22M | -951K | 2.39M | 3.28M | -1.15M |
| Pretax Income | -21.36M▲ 0% | -23.01M▼ 7.8% | -33.61M▼ 46.0% | -49.12M▼ 46.2% | -61.02M▼ 24.2% | -52.95M▲ 13.2% |
| Pretax Margin % | -374.45% | 2942.97% | -951.26% | -1779.71% | -2313.27% | -158.16% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -21.36M▲ 0% | -23.01M▼ 7.8% | -33.61M▼ 46.0% | -49.12M▼ 46.2% | -61.02M▼ 24.2% | -52.95M▲ 13.2% |
| Net Margin % | -374.45% | 2942.97% | -951.26% | -1779.71% | -2313.27% | -158.16% |
| Net Income Growth % | - | -7.77% | -46.03% | -46.16% | -24.23% | 13.22% |
| Net Income (Continuing) | -21.36M | -23.01M | -33.61M | -49.12M | -61.02M | -52.95M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.01▲ 0% | -0.02▼ 117.6% | -1.32▼ 7035.1% | -1.48▼ 12.1% | -1.66▼ 12.2% | -1.11▲ 33.1% |
| EPS Growth % | - | - | -7035.14% | -12.12% | -12.16% | 33.13% |
| EPS (Basic) | -0.01 | -0.02 | -1.32 | -1.48 | -1.66 | -1.11 |
| Diluted Shares Outstanding | 20.45M | 20.45M | 25.47M | 33.23M | 36.82M | 38.39B |
| Basic Shares Outstanding | 20.45M | 20.45M | 25.47M | 33.23M | 36.82M | 38.39B |
| Dividend Payout Ratio | - | - | - | - | - | - |
OBIO Balance Sheet
Orchestra BioMed Holdings, Inc. (OBIO) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|
| Total Current Assets | 36.25M | 11.32M | 84.69M | 89.11M | 69.17M | 107.91M |
| Cash & Short-Term Investments | 35.79M | 10.9M | 83.78M | 87.59M | 66.81M | 106.51M |
| Cash Only | 20.34M | 9.94M | 19.78M | 30.56M | 22.26M | 34.69M |
| Short-Term Investments | 15.45M | 958K | 64M | 57.04M | 44.55M | 71.82M |
| Accounts Receivable | 168K | 121K | 96K | 99K | 92K | 95K |
| Days Sales Outstanding | 10.75 | -56.48 | 9.92 | 13.09 | 12.73 | 1.04 |
| Inventory | 69K | 68K | 276K | 146K | 173K | 310K |
| Days Inventory Outstanding | 173.69 | 124.72 | 312.86 | 286.51 | 309.53 | 595.53 |
| Other Current Assets | 0 | 0 | 533K | 1.27M | 2.09M | 994K |
| Total Non-Current Assets | 1.84M | 2.21M | 10.88M | 6.1M | 7M | 6.95M |
| Property, Plant & Equipment | 1.03M | 1.12M | 3.68M | 2.83M | 3.49M | 3.21M |
| Fixed Asset Turnover | 5.55x | -0.70x | 0.96x | 0.97x | 0.76x | 10.43x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 185K | 398K | 2.5M | 2.5M | 2.5M | 2.5M |
| Other Non-Current Assets | 626K | 690K | 4.71M | 769K | 1.02M | 1.24M |
| Total Assets | 38.09M▲ 0% | 13.53M▼ 64.5% | 95.57M▲ 606.5% | 95.21M▼ 0.4% | 76.17M▼ 20.0% | 114.86M▲ 50.8% |
| Asset Turnover | 0.15x | -0.06x | 0.04x | 0.03x | 0.03x | 0.29x |
| Asset Growth % | - | -64.49% | 606.53% | -0.38% | -20% | 50.78% |
| Total Current Liabilities | 14.36M | 12.24M | 18.57M | 11.21M | 16.21M | 16.74M |
| Accounts Payable | 1.77M | 2.03M | 3.97M | 2.9M | 5.13M | 6.09M |
| Days Payables Outstanding | 4.47K | 3.72K | 4.5K | 5.69K | 9.19K | 11.71K |
| Short-Term Debt | 4M | 2M | 0 | 0 | 0 | 751K |
| Deferred Revenue (Current) | 5.8M | 5.54M | 6.44M | 2.51M | 4.44M | 0 |
| Other Current Liabilities | 2.18M | 780K | 4.57M | 2.66M | 2.61M | 15.98M |
| Current Ratio | 2.52x | 0.92x | 4.56x | 7.95x | 4.27x | 6.45x |
| Quick Ratio | 2.52x | 0.92x | 4.55x | 7.94x | 4.26x | 6.43x |
| Cash Conversion Cycle | -4.28K | -3.65K | -4.18K | -5.39K | -8.86K | -11.11K |
| Total Non-Current Liabilities | 72.27M | 72.52M | 24.47M | 15.96M | 27.01M | 34.74M |
| Long-Term Debt | 5.46M | 3.67M | 9.49M | 0 | 14.29M | 936K |
| Capital Lease Obligations | 0 | 0 | 1.68M | 1.04M | 1.69M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | -14.92M | 0 | 0 |
| Other Non-Current Liabilities | 51.69M | 51.99M | 196K | 14.92M | 40K | 33.81M |
| Total Liabilities | 86.63M | 84.76M | 43.04M | 27.17M | 43.22M | 51.48M |
| Total Debt | 9.46M | 5.67M | 11.87M | 1.69M | 16.53M | 1.69M |
| Net Debt | -10.89M | -4.26M | -7.91M | -28.87M | -5.73M | -33M |
| Debt / Equity | - | - | 0.23x | 0.02x | 0.50x | 0.03x |
| Debt / EBITDA | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - |
| Interest Coverage | - | -23.52x | - | - | - | - |
| Total Equity | -48.54M▲ 0% | -71.23M▼ 46.7% | 52.53M▲ 173.8% | 68.04M▲ 29.5% | 32.96M▼ 51.6% | 53.57M▲ 62.5% |
| Equity Growth % | - | -46.74% | 173.75% | 29.52% | -51.56% | 62.54% |
| Book Value per Share | -2.37 | -3.48 | 2.06 | 2.05 | 0.90 | 0.00 |
| Total Shareholders' Equity | -48.54M | -71.23M | 52.53M | 68.04M | 32.96M | 53.57M |
| Common Stock | 0 | 160M | 2K | 4K | 4K | 6K |
| Retained Earnings | -143.11M | -166.13M | -199.73M | -248.85M | -309.88M | -362.58M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -2K | -211.45M | -8K | -10K | 52K | 60K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
OBIO Cash Flow Statement
Orchestra BioMed Holdings, Inc. (OBIO) cash flow — operating, investing & free cash flow history
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|
| Cash from Operations | -26.18M | -19.43M | -29.29M | -46.13M | -50.56M | -48.96M |
| Operating CF Margin % | -459.11% | 2484.53% | -829.01% | -1671.27% | -1916.53% | -146.24% |
| Operating CF Growth % | - | 25.8% | -50.75% | -57.49% | -9.61% | 3.15% |
| Net Income | -21.36M | -23.01M | -33.61M | -49.12M | -61.02M | -52.7M |
| Depreciation & Amortization | 137K | 181K | 222K | 287K | 308K | 327K |
| Stock-Based Compensation | 221K | 302K | 3.41M | 7.63M | 10.62M | 11.98M |
| Deferred Taxes | 0 | 288K | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 2.93M | 217K | 1.14M | -1.61M | 308K | -8.57M |
| Working Capital Changes | -8.12M | 2.6M | -451K | -3.31M | -765K | 0 |
| Change in Receivables | -79K | 47K | 25K | -3K | 22K | -3K |
| Change in Inventory | -26K | 1K | -208K | 131K | -28K | -137K |
| Change in Payables | -2.61M | 1.08M | 0 | 145K | 2.97M | 4.87M |
| Cash from Investing | 26.97M | 13.02M | -64.12M | 10.69M | 13.09M | -26.94M |
| Capital Expenditures | -539K | -274K | -591K | -78K | -289K | -489K |
| CapEx % of Revenue | 9.45% | -35.04% | 16.73% | 2.83% | 10.96% | 1.46% |
| Acquisitions | -27.5M | -13.29M | 0 | 0 | -602K | 0 |
| Investments | - | - | - | - | - | - |
| Other Investing | 27.5M | 13.29M | 0 | 0 | 0 | 0 |
| Cash from Financing | 10M | -3.99M | 103.26M | 46.22M | 29.17M | 88.33M |
| Debt Issued (Net) | 10M | -4M | 3.55M | -10.85M | 15M | 0 |
| Equity Issued (Net) | 1000K | 0 | 1000K | 254K | 1000K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -162.29M | 7K | -10.13M | 56.81M | -864K | 88.33M |
| Net Change in Cash | 10.78M▲ 0% | -10.4M▼ 196.5% | 9.85M▲ 194.6% | 10.78M▲ 9.4% | -8.3M▼ 177.0% | 12.43M▲ 249.8% |
| Free Cash Flow | -26.72M▲ 0% | -19.7M▲ 26.3% | -29.88M▼ 51.7% | -46.2M▼ 54.6% | -50.85M▼ 10.0% | -49.45M▲ 2.7% |
| FCF Margin % | -468.56% | 2519.57% | -845.74% | -1674.09% | -1927.48% | -147.7% |
| FCF Growth % | - | 26.27% | -51.65% | -54.64% | -10.05% | 2.74% |
| FCF per Share | -1.31 | -0.96 | -1.17 | -1.39 | -1.38 | -0.00 |
| FCF Conversion (FCF/Net Income) | 1.23x | 0.84x | 0.87x | 0.94x | 0.83x | 0.92x |
| Interest Paid | 0 | 0 | 1.37M | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
OBIO Key Ratios
Orchestra BioMed Holdings, Inc. (OBIO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -63.97% | -81.47% | -120.84% | -122.4% |
| Return on Invested Capital (ROIC) | - | - | - | -92.2% | -145.26% | -162.6% |
| Gross Margin | 97.46% | 125.45% | 90.89% | 93.26% | 92.27% | 99.43% |
| Net Margin | -374.45% | 2942.97% | -951.26% | -1779.71% | -2313.27% | -158.16% |
| Debt / Equity | - | - | 0.23x | 0.02x | 0.50x | 0.03x |
| Interest Coverage | - | -23.52x | - | - | - | - |
| FCF Conversion | 1.23x | 0.84x | 0.87x | 0.94x | 0.83x | 0.92x |
| Revenue Growth | - | -113.71% | 551.79% | -21.88% | -4.42% | 1169.22% |
OBIO SEC Filings & Documents
Orchestra BioMed Holdings, Inc. (OBIO) SEC filings — annual & quarterly reports (10-K, 10-Q)
OBIO Frequently Asked Questions
Orchestra BioMed Holdings, Inc. (OBIO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Orchestra BioMed Holdings, Inc. (OBIO) reported $33.5M in revenue for fiscal year 2025. This represents a 487% increase from $5.7M in 2020.
Orchestra BioMed Holdings, Inc. (OBIO) grew revenue by 1169.2% over the past year. This is strong growth.
Orchestra BioMed Holdings, Inc. (OBIO) reported a net loss of $53.0M for fiscal year 2025.
Dividend & Returns
Orchestra BioMed Holdings, Inc. (OBIO) has a return on equity (ROE) of -122.4%. Negative ROE indicates the company is unprofitable.
Orchestra BioMed Holdings, Inc. (OBIO) had negative free cash flow of $49.5M in fiscal year 2025, likely due to heavy capital investments.
Explore More OBIO
Orchestra BioMed Holdings, Inc. (OBIO) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates